Navigation Links
Dehaier Strengthens Intellectual Property Portfolio
Date:6/27/2011

BEIJING, June 27, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it was granted three new patents by State Intellectual Property Office of the People's Republic of China ("SIPO"). The patent awards were related to the design of Dehaier's Sleep Diagnostic and Continuous Positive Airway Pressure ("CPAP") homecare medical products and Medical-grade Air Compressor. These patents were issued in June 2011 and are valid for 10 years.

(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO)

Design patents are granted to products that incorporate unique shapes, patterns, colors or combinations of features that strengthen a product's brand value upon commercialization. According to Patent Law of People's Republic of China, design patents are protected and defensible under national Intellectual Property Law.

"Innovation through continued R&D is key to supporting growth in our self-branded homecare business, and we believe these patent awards further protect our ability to provide the market with proprietary best-in-breed products. Developing new designs and enriching self-branded product offerings in the homecare segment is one of our key growth strategies to meet diversified market needs with portable, personalized and differential products," said Mr. Ping Chen, CEO of Dehaier, "These new patents bring our total intellectual property holdings to five patents and five software copyrights, in addition to other proprietary technology, such as trade secrets. Additionally, we currently have three pending patents and six pending software copyrights applications with SIPO for homecare products. We will continue to strengthen our R&D capabilities and plan to continue to build our intellectual property portfolio to increase our brand recognition, gain market share and continue growing our business. "

About Dehaier Medical Systems Ltd.Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier's technology is based on five patents and five software copyrights; additionally we have three pending patents and six pending software copyrights, and proprietary technology. More information may be found at http://www.chinadhr.com.

Forward-looking StatementsThis news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.Contact UsIn the US:The Piacente Group, Inc.Investor RelationsBrandi Floberg or Lee RothPhone: +1-212-481-2050Email: dehaier@tpg-ir.com In China:The Piacente Group, Inc.Investor RelationsWendy SunPhone: +86-10-6590-7991Email: dehaier@tpg-ir.com Dehaier Medical Systems LimitedRita LiuCFOPhone: +86-10-8844-5026Email: liuz@dehaier.com.cn
'/>"/>

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Systems Announces Closing of Initial Public Offering on NASDAQ
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. Dehaier Medical Systems Announces New Exclusive China Distribution Agreement with Welch Allyn, Further Broadening Companys Product Lines
4. Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell
5. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
6. Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line
7. Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27
8. Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
9. Dehaier Medical Shows New Products at 2010 China International Medical Equipment Fair
10. Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project
11. Dehaier Medical to Participate in MEDICA International Trade Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... today announced an exhibitor sponsorship at MobileIron Live! 2017 in Santa ... technologies for an immersive, educational approach to helping organizations maximize the benefits of ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... outcomes, today released the podcast, “Make Plans for MACRA,” highlighting the ... into the physician's office and how physicians and other clinicians are reimbursed for ...
(Date:4/26/2017)... ... 2017 , ... CareSet Labs today is releasing an important ... Part D Medicare data. The dataset, called PaPR (Providers and Prescribing Records) details ... paper. The PaPR (pronounced "paper") data set aggregates this information on a ...
Breaking Medicine News(10 mins):